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There is increasing evidence that T lymphocytes play a key role in controlling endogenous
regeneration. Regeneration appears to be impaired in case of local accumulation of
CD8+ effector T cells (TEFF), impairing endogenous regeneration by increasing a primary
“useful” inflammation toward a damaging level. Thus, rescuing regeneration by regulating
the heightened pro-inflammatory reaction employing regulatory CD4+ T (TReg) cells
could represent an immunomodulatory option to enhance healing. Hypothesis was that
CD4+ TReg might counteract undesired effects of CD8+ TEFF. Using adoptive TReg
transfer, bone healing was consistently improved in mice possessing an inexperienced
immune system with low amounts of CD8+ TEFF. In contrast, mice with an experienced
immune system (high amounts of CD8+ TEFF) showed heterogeneous bone repair with
regeneration being dependent upon the individual TEFF/TReg ratio. Thus, the healing
outcome can only be improved by an adoptive TReg therapy, if an unfavorable TEFF/TReg
ratio can be reshaped; if the individual CD8+ TEFF percentage, which is dependent
on the individual immune experience can be changed toward a favorable ratio by the
TReg transfer. Remarkably, also in patients with impaired fracture healing the TEFF/TReg
ratio was higher compared to uneventful healers, validating our finding in the mouse
osteotomy model. Our data demonstrate for the first time the key-role of a balanced
TEFF/TReg response following injury needed to reach successful regeneration using bone
as a model system. Considering this strategy, novel opportunities for immunotherapy in
patients, which are at risk for impaired healing by targeting TEFF cells and supporting
TReg cells to enhance healing are possible.
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INTRODUCTION
The most promising healing scenario for a damaged tissue would be self-repair, thus to regenerate.
Bone is able to heal without scar formation and therefore has a high regenerative capacity (1).
Therefore, the healing process after bone injury could serve as a blue print for understanding
underlying mechanisms guiding successful tissue regeneration. The majority of bone fractures heal
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by endochondral ossification, which is usually divided into
five distinct but overlapping stages. Bone healing starts with
an initial hematoma formation and inflammation (further
divided into pro- [1] and anti-inflammation [2]), subsequent
revascularization of the fracture area and cartilage formation
(soft callus formation [3]) occurs. Chondrocyte hypertrophy and
matrix calcification proceed its replacement by newly formed
woven bone (hard callus formation [4]). The final step of the
healing cascade is the remodeling [5] of the new formed bone
in dependence on the mechanical stimuli during loadbearing.
In this generally successful healing of bone, immunological cells
play a core role and impact the cascades of regeneration across all
of these stages.
Despite its significant endogenous regeneration potential, in
a meaningful proportion of humans (10–15%) fracture healing
does not succeed and results in delayed union or persistent
non-union (2, 3). This still represents a considerable health
care problem, specifically in the aging industrial societies (4).
After fracture, the initial pro-inflammatory reaction dominated
by M1 macrophages and Th1T cells and their chemokine and
cytokine release pattern initiates the infiltration of cells needed
for a successful repair process (5, 6).The switch from an initial
pro-inflammatory to a subsequent anti-inflammatory state has
been proven to be the key to any successful healing (7). There
is growing evidence that the adaptive immunity, in particular,
T cells, contributes to endogenous regeneration even in the
absence of infections (8, 9) by modulating the local cytokine
milieu in the fracture gap (8, 10–15) and thus during this early
inflammatory phase. Using samples from fracture patients, it
was recently shown that a higher amount of CD8+ effector T
cells (TEFF) is associated with a prolonged pro-inflammatory
reaction and impaired fracture repair (16, 17). Accordingly,
systemic depletion of CD8+ T cells in a mouse osteotomy
model enhanced endogenous fracture regeneration, whereas the
adoptive transfer of CD8+ T cells impaired the regeneration
process. Therefore, high CD8+ T effector cell percentages are
critical for an uneventful healing.
Important counterparts of an unfavorable pro-inflammatory
immune response are CD4+ regulatory T cells (TReg).
CD4+ TReg are a highly specialized cell population with
immunomodulatory functions and are characterized by the
expression of the surface marker CD25 and the transcription
factor Forkhead-Box-Protein P3 (FOXP3) (7, 18–21). These
cells are essential for the maintenance of the immunological
self-tolerance, but also to prevent overwhelming inflammation
in response to pathogens and in response to tissue injury. Several
studies show that CD4+ TReg might control osteoclast activity
and as result osteoarthritis, and enhance bone formation as
well as inhibit bone loss under physiological and pathological
conditions (19–21). CD4+ TReg execute immunomodulatory
functions by multiple mechanisms, such as cell-cell contact
dependent and independent ones. Their direct impact on the
ATP metabolism via the surface molecules CD39 and CD73
results in the generation of strong immunomodulatory ATP
derivatives, such as adenosine, and might be of particular
interest for their immune-regulatory potency in inflamed tissues.
Adenosine inhibits cytokine secretion by and proliferation of
activated TEFF cells as well as the switch of tissue resident M2
macrophages to pro-inflammatory M1 macrophages (22–24).
With the growing evidences that activated TEFF negatively
impact regenerative processes, their counterparts, the CD4+
TReg might have a positive regulatory impact on endogenous
regeneration. In fact, there are a couple of studies showing their
pro-regenerative potency e.g., after myocardial infarction or in
regeneration from myocarditis (22).
We hypothesize that CD4+ TReg possess the potential to
reshape and further to rebalance an initial unfavorable and “anti-
regenerative” immune status (e.g., created by an increased CD8+
TEFF level) into a pro-regenerative state promoting successful
bone healing after fracture.
The role of the adaptive immunity in regeneration was
overlooked for a long time, mainly because of using mouse
models with a naïve T cell phenotype (23). Conventionally,
specific pathogen free (SPF) housing is applied to have more
standardized conditions. However, this housing is silencing the
adaptive immunity, and even >1 year old SPF mice express
an almost naive immune system lacking TEFF cells as seen in
newborns or babies but not comparable to adult human beings
who are permanently exposed to environmental challenges (24).
We further hypothesize that immune experienced mice kept
under non-SPF, and thus pathogen exposed, conditions are the
clinically more relevant model for studying the role of the
TEFF/TReg balance in bone regeneration.
Within this study the interplay of CD8+ TEFF and CD4+
TReg was analyzed using immunologically naïve SPF housed
mice (low CD8+ TEFF) and non-SPF housed animals (high
percentage of TEFF) to mimic the impact of immune experience.
Finding were compared to human fracture samples from
patients with a known undisturbed healing and a diagnosed
delayed healing outcome. Findings demonstrate the significant
impact of a balanced TEFF/TReg ratio on bone regeneration




To evaluate the potential of CD4+ TReg to reshape an initial
unfavorable and “anti-regenerative” immune state into a “pro-
regenerative” one, we went into our well-established mouse
osteotomy model system. Freshly isolated murine CD4+ TReg
were adoptively transferred into mice prior to osteotomy. The
healing outcome was investigated 21 d post-surgery. To have
a clinically more relevant mouse model, we included for the
immunomodulatory approach an osteotomy model using mice
possessing a more experienced adaptive immune system (n =
20; control: n = 6, with adoptive CD4+ TReg transfer: n = 15
[non-SPF housing]) compared to the classically used naïve mice
(n = 12; control: n = 6, with adoptive CD4+ TReg transfer: n
= 6 [SPF housing]). One mouse was excluded from the study
due to a non-evaluable healing outcome as a consequence of a
failed fixation. In the non-SPF housed mice, the CD8+ TEFF
to CD4+ TReg ratio was evaluated by flow cytometry pre- as
well as post-osteotomy to investigate the interplay of the cell
Frontiers in Immunology | www.frontiersin.org 2 August 2019 | Volume 10 | Article 1954
Schlundt et al. T Cell Ratios Impact Regeneration
ratio and the healing outcome (Figure S1: Study design of the
mouse experiment).
We included data from human fracture patients to confirm
the murine findings in a patient setting. Thirty-five patients
(aged 19–77 years, 19 male, and 16 female) were included
in this study. Due to the assessment of immunological
parameters, patients with human immunodeficiency virus
infection, hepatitis infection, ongoing, or past (within 5 years)
malign diseases/treatments were excluded from the study. To
ensure a similar post-surgery physiotherapeutically mobilization,
patients with polytrauma or several fractures (>2 fractures)
were also excluded from the study (see Table 1, Tables S1, S2).
Based on the radiological data, fracture patients were divided
into normal (n = 23) and impaired (n = 12) healing
fractures. To analyze the interplay of the CD8+ TEFF to
CD4+ TReg ratio and the healing outcome, peripheral blood
samples were taken prior to surgery, and the TEFF/TReg was
analyzed by flow cytometry. In addition, the cell ratio was
also investigated in fracture hematoma samples, taken during
the surgery.
Characteristics of the Animal Model Used
for Immune Intervention Approaches
Female C57BL/6 mice (Charles River Laboratories, Wilmington,
USA) of an age of 12 weeks were used for the animal experiments.
Mice were kept in small groups under specific pathogen free
(SPF) or non-SPF (area in the animal facility without an
additional barrier and filtered air supply for the mice cages)
housing conditions. A controlled temperature (20 ± 2◦C) and a
12 h light/dark circle were present. Food and water were available
ad libitum. All animal experiments were approved by the local
legal representatives (Landesamt für Gesundheit und Soziales
Berlin: G0008/12; T0119/14; T0249/11) and done accordingly to
the guidelines of the Animal Welfare Act, the National Institutes
of Health Guide for Care and Use of Laboratory Animals, and
the National Animal Welfare and ARRIVE Guidelines. Health
monitoring followed the FELASA guidelines for both housing
conditions—no health risks were monitored for those animals
housed under non-SPF conditions.
CD4+ TReg were enriched by cell sorting (see below) and
adoptively transferred (5–8 × 105 cells) via the tail vein prior
to surgical intervention. Mice were randomly allocated to the
treatment groups.
TABLE 1 | Characterization of the patients.
Parameter Impaired healing
patients (n = 12)
Normal healing
patients (n = 23)
Significance




Height (m) 1.71 ± 0.09 1.74 ± 0.09 0.3
Weight (kg) 79.63 ± 18.52 76.43 ± 15.79 0.6
BMI 27.3 ± 5.9 25.2 ± 4.2 0.2
Surgical Approach and Performing the
Mouse Osteotomy
A non-critical sized osteotomy was set in the left femur of the
mice as described before (6). In short, mice were anesthetized by
inhalation of isoflurane and received a subcutaneous injection of
the analgesic Buprenorphine (0.03 mg/kg) and of the antibiotic
Clindamycin (45 mg/kg). After shaving the surgery field and
disinfection, a longitudinal cut of the skin was performed. The
femur was bluntly exposed and the external fixator, consisting of
four pins and a bar (RISystem, Davos, Switzerland), wasmounted
on the lateral side of the femur. An osteotomy of 0.7mm was
created between the two middle pins using a wire saw. The skin
was sutured, and the mice were brought back into their cages. As
post-operative analgesia, tramadol hydrochloride (25 mg/l) was
added to the drinking water for 3 days post-surgery.
Isolation of Murine Regulatory T Cells for
Immunotherapy
Murine CD4+ regulatory T cells (TReg) were isolated bymagnetic
activated cell sorting (MACS) from pooled cells derived from
the spleen and the lymph nodes: inguinal nodes, axillary
nodes, brachial nodes, and mesenteric nodes. A single cell
suspension was prepared and erythrocytes were lysed. The
isolation procedure was carried out with the CD4+ TReg isolation
kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany),
according to the manufactures instructions. Briefly, the cell
suspension was incubated with a biotin-labeled antibody mix
to stain all non-CD4+ T cells. Afterwards, α-biotin magnetic
beads, as well as a PE-labeled α-CD25 antibody were added to
the cells. After incubation, cells were washed (8min, 1,500 rpm,
4◦C), resuspended in MACS buffer (1x PBS+ 0.5% BSA+ 2mM
EDTA) and transferred to an LD column (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany), which was placed in a magnetic
field. The flow through was collected, washed, resuspended in
MACS buffer and incubated with an α-PE antibody. Cells were
washed, resuspended in MACS buffer and transferred to an MS
column (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany),
which was placed in a magnetic field. CD4+ TReg, which were
kept in the magnetic field in the column, were flushed out,
washed and counted. Subsequently, CD4+ TReg were isolated
with a purity of ≥85%.
Regulatory T Cell Suppression Assay
The suppressive capacity of freshly isolated CD4+ TReg was
tested in a co-culture setup with CD4+CD25- responder T
cells (TResponder). TResponder were labeled with a cell proliferation
dye (Cell Proliferation Dye (CPD) eF450, eBioscience, San
Diego, USA) following the protocol. In short, MACS isolated
TResponder were washed (8min, 1,500 rpm, RT) twice with PBS
and resuspended in a solution consisting of pre-warmed PBS
and a 10mM CPD eF450 solution to a final concentration
of 10 × 106 cells/ ml. Cells were incubated for 20min at
RT in the dark and the staining was stopped by the addition
of ice cold cell culture media [RPMI 1640 (Biochrom AG,
Berlin, Germany) + 10% FBS superior (Biochrom AG, Berlin,
Germany)+ 1% penicillin/streptomycin (Sigma-Aldrich Chemie
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GmbH, München, Germany), and 50µM β-Mercaptoethanol
(Sigma-Aldrich Chemie GmbH, München, Germany)]. Cells
were incubated for 5min on ice, washed three times with pre-
warmed cell culture media and counted. For the suppression
assay, 0.75 × 105 labeled TResponder were co-cultured in cell
culture media with (1) 1.5 × 105 or (2) 0.15 × 105 CD4+
TReg in a 96 well plate. TResponder were also cultured alone. In
order to stimulate the proliferation of TResponder, α-CD3 and
α-CD28 (both eBioscience, San Diego, USA) were plate-bound
(each 5µg/ml) to the wells before adding the co-culture setups.
After 2–3 days, cells were harvested, and the proliferation of the
TResponder was analyzed by flow cytometry. The suppression of
the CD4+ TReg was calculated based on the proliferation of the
TResponder which were cultured alone. Their proliferation was set
to 100, and the proliferation of the co-cultured TResponder was
calculated relative to it. Finally, the percentage of suppression was
defined as 100 minus the (relative) proliferation.
Flow Cytometry Analysis of Murine
Immune Cells in Tissue Samples
The sample preparation for flow cytometry was done as follows:
from the spleen, the bone marrow, and the lymph nodes, single
cell suspensions were prepared. The spleen was cut into small
pieces and carefully pushed through a cell strainer. For the
bone marrow, the ends of the bones were cut and the marrow
was flushed out with a syringe. Afterwards, the bone marrow
cells were also carefully pushed through a cell strainer. Lymph
nodes were directly pushed through a cell strainer. All single
cell suspensions were washed in PBS, and the erythrocytes were
lysed. Blood samples were centrifuged (10min, 2,000 rpm, RT),
the supernatant was removed, and erythrocytes were lysed. Cells
were washed in PBS (10min, 1,500 rpm, 4◦C) and stained. Lysed
and washed cells were resuspended in PBS and incubated with
a LIVE/DEAD staining kit (Thermo Fisher Scientific, Waltman,
USA) for 30min on ice. For the evaluation of the adoptive
CD4+ TReg transfer (1 and 21 days post-osteotomy) and the
amount of CD4+ TReg in the harvested tissues after 21 days of
healing, cells were washed, resuspended in PBS/BSA (1x PBS +
1% BSA and 0.1% sodium azide) and stained with the following
antibody mix for 20min on ice: α-CD3 PerCP (BioLegend, San
Diego, USA), α-CD4 AF700 (eBioscience, San Diego, USA) and
α-CD25 APC (BioLegend, San Diego, USA). For the evaluation
of the CD4+ and CD8+ effector T cell subset, cells were washed,
resuspended in PBS/BSA and stained with the following antibody
mix for 20min on ice: α-CD3 PerCP (BioLegend, San Diego,
USA), α-CD4 AF700 (eBioscience, San Diego, USA), α-CD8
eF450 (eBioscience, San Diego, USA), α-CD44 PE-Cy7 (Becton
Dickinson Bioscience, Heidelberg, Germany), α-CD62L APC
(BioLegend, San Diego, USA) and α-CD25 APC (BioLegend, San
Diego, USA). Cells were washed, resuspended, and either fixed
for 20min at RT with a 2% formaldehyde solution (evaluation
of adoptive CD4+ TReg transfer) or permeabilized with a
fixation/permeabilization buffer (eBioscience, San Diego, USA)
for 1 h on ice (evaluation of the amount of CD4+ TReg after
21 days). Cells were washed twice with permeabilization buffer
(eBioscience, San Diego, USA), resuspended and incubated for
30min on ice with α-Foxp3 FITC (eBioscience, San Diego,
USA). After fixation and permeabilization, cells were washed,
resuspended and analyzedwith the LSR II flow cytometer (Becton
Dickinson Bioscience, Heidelberg, Germany) (for the gating
strategy please refer to Figure S2).
Micro-Computed Tomography of
Osteotomized Mouse Bones
To evaluate the formation of newly formed bone, µCT analyses
were performed with the osteotomized bones 21 days post-
surgery. The harvested bones were scanned in a µCT Viva
40 (SCANCO Medical AG, Brüttisellen, Switzerland). The
volume of interest (VOI) included 190 slices around the former
osteotomy gap. The following parameters were used for the scan:
10.5µm voxel size, 55 keVp peak voltage energy and an applied
current of 145 µA. In order to be able to distinguish between
non-mineralized and mineralized bone, a gray value threshold
was used (25). A defined threshold of 396.9mg hydroxyapatite
per cm2 identified mineralized bone.
Patients and Study Protocol
The study was performed in compliance with the International
Conference on Harmonization Guidelines for Good Clinical
Practice and the Declaration of Helsinki. All patients participated
with a written informed consent, and the study was approved
by the Institutional Review Board (IRB) of the Charité –
Universitätsmedizin Berlin (IRB approval EA2/096/11). All
patients received a complete study follow up rate including all
clinical investigation time points and radiological assessments.
Moreover, all patients were matched according to age, sex,
fracture type and initial surgical treatment strategy. The
demographic and clinical characteristics of the included patients
are shown in Table 1, Tables S1, S2. To monitor the fracture
healing process and in consensus with established clinical
examination time points, the patients were investigated pre-
surgery and after 4–6, 12, 17–19, 24, and 52 weeks. Regarding
the fracture treatment, the only significant difference between the
healing groups was the number of surgical interventions required
(p= 0.003; Table S2).
Healing Classification and Data Collection
Time-dependent criteria: A fracture was categorized as impaired
healing when it was not completely healed after 17–19 post-
operative weeks based on the callus formation. Radiological
criteria: Different criteria were applied to identify an impaired
healing fracture by radiological analyses: (A) incomplete fracture
healing or the absence of visible bone consolidation on a simple
X-ray after 17–19 post-operative weeks; (B) the presence of a
resorption zone or incomplete callus formation; (C) incomplete
bridging, which means one to three cortices bridged; or (D) no
bridging, which means no cortex is bridged.
Every patient underwent consecutive x-ray analyses to assess
the stability of the implant and to observe the fracture gap
throughout the study time. Appraisal of x-rays was performed by
three independent, blinded specialists (two orthopedic surgeons
and one radiologist), to ensure the healing outcome and the
classification of patients as shown in Table 1. To fulfill the
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definition of impaired healing, patients had to meet one or more
of the time dependent- and/or radiological criteria as stated
above (26–29).
Flow Cytometry Analysis of Human Blood
Samples to Characterize Immune Status in
Fracture Patients
Blood samples were taken before the surgery after 15min
rest in a supine position. All blood samples were immediately
moved into a dark, air-conditioned room, and sent to the
laboratory within 2 h. Additionally, plasma and serum samples
were collected in aliquots and frozen at −80◦C. Full blood
count and standard clinical variables (erythrocytes, hemoglobin,
hematocrit, thrombocytes, creatinine, sodium, potassium, urea,
chloride, GPT, GOT, gamma-GT, TSH, CRP) were measured
immediately in plasma and serum samples according to the
laboratory standard operating procedures.
To evaluate the adaptive immunity of the patients, we
applied our recently developed and extensively validated pre-
cocktailed dried DuraClone T cell panels (Beckman Coulter),
including the “T cell panel” CD45RA, CCR7, CD28, PD1, CD27,
CD4, CD8, CD3, CD57, CD45, and “regulatory T cell panel”
(Beckman Coulter), including CD45RA, CD25, CD127, CD39,
CD4, FOXP3, CD3, CD45 were used. Flow cytometry analysis
was performed using the BC NAVIOS 10/3 flow cytometer
and data were analyzed using BC Kaluza analysis software
(Beckman Coulter).
Human Genomic DNA (gDNA) Purification
for Epigenetic Analysis
Frozen human fracture hematoma samples (n = 8) were thawed
in a 37◦C water bath and further kept on ice. To dissolve the
hematoma samples, Clotspin R© Baskets from Qiagen were used
according the manufacturing protocol: Purification of archive-
quality gDNA from clotted whole blood using Clotspin R© Baskets
and the Gentra R© Puregene R© blood kit provided by Qiagen. All
protocol steps were followed according to the manufacturer’s
instructions. Steps included the usage of isopropanol and
Glycogen Solution (20 mg/ml from Qiagen) and washing of
gDNA pellets with 70% ethanol. gDNA was further air dried
at room temperature until no remaining fluids remained.
gDNA was incubated with 500 µl DNA hydration solution
provided within the kit (www.qiagen.com/literature/handbooks/
default.aspx). gDNAwas incubated at 65◦C until it was dissolved.
gDNA quality and quantity were confirmed using the
NanoDrop-ND-1000 system (PEQLAB GmbH). Samples were
stored at−80◦C until further experiments.
Epigenetic qPCR Analysis (Patients)
Purified genomic DNA from the fracture hematoma (n = 8)
was converted using the EpiTect Fast Bisulfite Conversion Kit
(Qiagen) following the manufacturer’s instructions. CD3+, TReg
-specific and CD8B+ T cell-specific epigenetic qPCR analyses
were performed as previously described (30–32).
Statistics
For the statistical evaluation of the data, the program SPSS
(Version 22; IBM Deutschland GmbH, Ehningen, Germany)
was used. Unless otherwise stated, all data were represented as
means± SD.
Human Data
The Levene test was used to assess the homogeneity of variances
of the data for the indicated groups and the data were then
analyzed using the unpaired Student’s t-test (two groups).
Mouse Data
Due to the small sample sizes, a normal distribution of the data
was excluded. Therefore, the Mann-Whitney U-test was used
as statistical test. If more than two samples were compared,
the significance value p was corrected by using the Bonferroni
correction. Data were seen as statistically significant if p ≤
0.05 or if p ≤ 0.05/n (n = number of compared samples)
(Bonferroni corrected data). Data are presented as scatter or
boxplot graphs. Usage of the Bonferroni correction is indicated
in the respective figures.
Data and Materials Availability
All data needed to evaluate the conclusions in the
paper are presented within the paper and/or in the
Supplementary Materials. Additional data related to this
paper may be requested from the corresponding author.
RESULTS
In a small cohort of patients, we previously showed that CD57+
CD8+ TEMRA cells were markedly elevated in peripheral blood
of patients suffering from an impaired bone healing (17). T cell
receptor stimulation or IL-12 (bystander activation) can trigger
TEMRA cells to produce inflammatory cytokines, like IFNγ and
TNFα, without the need of antigen-presenting cells (independent
on co-stimulatory signals via CD28 or CD40L), making those
ideal candidates for enhancing intra-tissue inflammation if they
accumulate after injury. It is well-established that TReg play a
crucial role in controlling immune response at multiple levels
to prevent undesired immune reactivity, such as auto/allo-
immunity and infection-related pathogenesis (33). There is
increasing evidence that they are also pivotal in controlling
regenerative processes (34). Therefore, we wondered whether
adoptive transfer of CD4+ TReg might be a relevant option to
enhance fracture healing. To address this we applied a well-
defined mouse osteotomy model (35) and adoptively transferred
CD4+ TReg.
Application of CD4+ Regulatory T Cells as
Potential Agent to Improve Bone Fracture
Healing in SPF Mice
Prior to adoptively transferring the CD4+ TReg, we tested
the functionality of ex vivo enriched murine CD4+ CD25++
Foxp3+ TReg. Using an established CD4+ TReg suppression assay
in which freshly isolated CD4+ TReg (purity ≥85%, Figure S3)
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FIGURE 1 | Enhancing bone healing by adoptive transfer of murine CD4+ TReg in SPF mice. (A) Demonstration of the functionality of isolated murine CD4+ TReg in a
suppression assay, illustrated is the suppression of the proliferation of CD4+CD25- TResponder cells by using freshly isolated CD4+ TReg (n = 6). (B) Status of CD4+
TReg in the peripheral blood of the experimental mice 1 d after adoptive transfer, control (n = 6) vs. CD4+ TReg enriched mice (n = 6). (C,D) Improved bone healing
by adoptive CD4+ TReg transfer as demonstrated by µCT evaluation after 21 d, control (C, left, control SPF) vs. TReg enriched mice (C, right, +TReg SPF).
Quantification of the µCT data revealed a significantly higher BV/TV in the mice that received a CD4+ TReg transfer (+TReg) (n = 6) compared to the control SPF mice
(n = 5) (D). BV, bone volume; TV, total callus volume; BV/TV, ratio of BV to TV; Mann-Whitney U-test.
and stimulated TResponder (non-TReg) cells were co-cultured, we
confirmed their suppressive properties (Figure 1A).
In order to confirm the successful transfer of the CD4+ TReg
their fate was analyzed in the recipient mice. After infusion of
CD4+TReg into the tail vein of C57BL/6mice prior to osteotomy,
a blood sample for counting circulating CD4+ TReg was taken
1 day (1 d) after surgery. A significantly higher percentage of
CD4+CD25++ T cells (representing CD4+ TReg) was found
in animals that received an adoptive transfer in comparison
to control mice (Figure 1B) illustrating the efficacy of adoptive
transfer of TReg (p= 0.015).
After proving the feasibility of isolation, transfer and
functionality of adoptively transferred CD4+ TReg, we tested our
hypothesis that these cells had a positive impact on bone healing.
Initially we used SPF mice (12 weeks), where skeletal growth
was nearly completed and peak bone mass has almost been
reached (36). Further, an osteotomy model was used that did not
results in complete healing within 21 days and thus allows to
detect improvements in healing in comparison to control mice.
As expected, all control mice expressed a healing with a partly
visible osteotomy gap, as documented by µCT data (Figure 1C).
The experiment confirmed our hypothesis showing improved
bone healing at 21 d as indicated by a significantly increased
ratio of bone volume to total callus volume (BV/TV) in the
osteotomized femura of mice that received an adoptive transfer
of CD4+ TReg (Figure 1D; p= 0.017).
In summary, the elevation of the CD4+ TReg in recipient
mice showed a positive effect on bone healing. However, these
mice were kept under the usual SPF housing conditions resulting
in a “naïve” T cell system. In contrast, human beings are
permanently exposed to environmental antigens shifting their T
cell composition to higher TEFF cell counts in an age-dependent
manner (32). Therefore, alternative murine osteotomy models
are required that better reflect the situation in human patients.
Establishment of a Clinically More
Relevant Murine Model Applying Non-SPF
Housing to Generate an “Experienced” T
Cell Immunity Reflected by Enhanced TEFF
Cell Counts
Recently, we established a new model of non-SPF housing
conditions inducing a fast switch to a more “experienced” T cell
immunity with enhanced levels of TEFF cells (24, 37). Briefly,
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mice were transferred toward a non-barrier housing exposing
them to environmental pathogens. Thus, the environmental
microbial exposure was raised in comparison to the SPF
housed mice and the adaptive immune system was challenged.
TNAIVE/TMEMORY/TEFF counting in a blood sample before
osteotomy allows individual proof of “immune aging,” of immune
experience. It is worth mentioning that after 5 years of experience
with this model, no clinical abnormality was reported in these
mice nor has any serological disease status been recorded in this
cohort outside of an SPF barrier.
After a minimal exposure of 4 weeks, the immune
cell composition in these non-SPF housed animals was
analyzed and compared to that of SPF housed animals.
Although there is a significant individual variation, mice
developed a higher level of TEFF (both CD4+ and CD8+)
in immune tissues, e.g., spleen. Thus, the exposure led
to an altered CD8+ TEFF/CD4+ TReg ratio in non-
SPF mice compared to SPF mice (spleen: p = 0.008;
Figure S4).
In the next step, we asked whether an adoptive transfer of
CD4+ TReg could enhance bone healing in these mice with a
more experienced immune system and a consecutively higher
percentage of CD8+ TEFF.
Adoptive Transfer of CD4+ TReg in Mice
With an Experienced Adaptive Immunity
Results in Heterogeneous Bone Healing
Outcome
Similar to the TReg transfer in SPF housed animals, we used
mice with an experienced adaptive immunity to evaluate the
therapeutic potential of CD4+ TReg to further bone regeneration.
Animals received CD4+ TReg isolated from pooled donor
mice to prevent heterogeneity of individual TReg donors
(Figure 2A; +TReg). In contrast to the clear data received
from the SPF housed mice, non-SPF housed animals displayed
a heterogeneous clustered healing outcome after CD4+ TReg
transfer and osteotomy (Figures 2A–D). Remarkably, in half
of the mice, referred to as +TReg responders, healing was
significantly enhanced compared to control animals, illustrated
by an increased TV (p = 0.01), BV (p = 0.01) and ratio of BV
to TV (p = 0.038). In contrast, in the other half of the mice,
the healing was not improved, but even showed a worsening
(named “+TReg non-responders”) with significantly reduced TV
(p= 0.01) and BV (p= 0.01).
In order to determine the reason behind the distinct healing
differences of + TReg responders and non-responders several
FIGURE 2 | Heterogeneous impact of adoptive transfer of CD4+ TReg on bone healing outcome in mice kept under non-SPF housing conditions. (A–D) µCT
evaluation of the healing outcome after adoptive CD4+ TReg transfer after 21 d. (A) Representative images of the analyzed volume of interest of the healing bones are
shown. +TReg treated mice clustered into responder (+TReg left, n = 4) and non-responder (+TReg right, n = 4). Control mice showed no complete bridging after 21
d (left, control, n = 6). In contrast, +TReg responder showed complete bridging, whereas non-responder showed no bridging. (B–D) Quantification of the µCT
analysis, + TReg responder vs. + TReg non-responder vs. control mice. (E–G) Evaluation of the immune cell composition of +TReg responder vs. non-responder 21 d
post-surgery. (E) Confirmation of CD4+ TReg engraftment in both, +TReg responder and non-responder compared to the control. (F,G) +TReg non-responder
showed an elevated percentage of CD8+ TEFF (F) as well as a significantly higher ratio of CD8+ TEFF /CD4+ TReg (G) in the peripheral blood in comparison to the
+TReg responder. TV, total volume; BV, bone volume; BV/TV, ratio of BV to TV; Mann–Whitney U-test, Bonferroni correction (B–E).
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possibilities were analyzed. Differences in the functionality of
the transferred TReg can be ruled out as we used pooled cells
from several donor animals and saw responders and non-
responders among the recipients of the same cell pool. Recipients
were chosen from the same cage and randomly placed within
the treatment groups—no correlation with responder or non-
responder were found. Up to four animals were operated on at
each surgery day and no correlation with the surgical sequence
was found. Subsequently, we analyzed whether adoptively
transferred TReg showed reduced engraftment in the non-
responder mice. However, as shown in Figure 2E, the number of
TReg detectable at day 21 post TReg infusion and osteotomy did
not show a heterogeneous distribution and non-responder and
responder mice showed comparably elevated TReg level.
Interestingly, upon analysis of the immune cell
composition higher frequencies of CD62L-CD44+CD25+
activated CD8+ TEFF cells were found in the non-
responder animals, demonstrating that the immune
experience within the group of mice even within the
same cage was highly individual. A significantly elevated
TEFF/TReg ratio in peripheral blood of +TReg non-
responder vs. responder mice (p = 0.029; Figures 2F,G),
indicating that the TReg treatment was not sufficient to
reshape the negative effect of the CD8+TEFF cells in the
non-responder animals.
To test this assumption, we analyzed this ratio of TEFF/TReg
pre-operatively in the peripheral blood of another cohort of
seven non-SPF housed mice. We performed the adoptive CD4+
TReg transfer, set the osteotomy and evaluated the healing
outcome after 21 d as described before.Within this second cohort
of osteotomized mice the heterogeneous healing outcome of
the previous experiment was confirmed. The healing outcome
21 days after osteotomy again showed +TReg responder and
+TReg non-responder. Four mice could be clearly categorized
as +TReg responders (good healing outcome: bridging of
the cortices in progress) and three mice were classified as
+TReg non-responders (poor healing outcome: no bridging of
the cortices). Based on this grouping, we compared values
of the pre-surgery CD8+TEFF/CD4+TReg cell ratio with the
µCT evaluation after 21 d (BV/TV) (Figure 3A). Notably,
all four responder mice had a pre-surgery ratio of CD8+
TEFF/CD4+ TReg of <0.07 (below the dashed line) which
consistently correlated with a higher BV/TV in comparison
with the non-responder mice which showed a ratio of 0.08–
0.23 (above the dashed line). We further evaluated this CD8+
TEFF/CD4+ TReg ratio at 1 d post-surgery. Remarkably, CD4+
TReg transfer could not reverse the unfavorable ratio in the
non-responder mice (Figure 3B). Again, we could exclude
unsuccessful engraftment of the adoptively transferred CD4+
TReg as shown in Figure 3C.
The presented data suggest that successful bone regeneration
depends on the balance between CD8+ TEFF/CD4+
TReg. The cut off between +TReg responder and +TReg
non-responder however is not pronounced. In order to
confirm the results from the mouse experiment that the
CD8+ TEFF/CD4+ TReg ratio is a decisive factor for
the bone healing outcome the immune cell composition
in a patient cohort with a known healing outcome
was analyzed.
Elevated CD8+ TEMRA Level in the
Peripheral Blood of Patients With Impaired
Healing After Bone Fracture
In accordance with the mouse experiment, a patient cohort
with a high CD8+ TEFF level should be included in the
experiment to confirm our mouse data. Therefore, a
new patient cohort was recruited applying our previously
published (17) strategy to define delayed healing by functional
and radiological methods (Figures 4C,D). In a first step
elevated CD8+ TEFF level were confirmed in the new
patient cohort, the cells were further subtyped as TEMRA
cells CD45+CD3+CD8+CD57+CD28- (Figure 4A). The
impaired healing group showed an almost three times higher
proportion of circulating CD45+CD3+CD8+CD57+CD28-
TEMRA cells (p < 0.001).
FIGURE 3 | Individual effector/regulatory T cell ratio pre-osteotomy determines the healing outcome in mice. (A) Mice having a lower pre-surgery CD8+ TEFF to
CD4+ TReg ratio (left y-axis) showed a higher BV/TV (right y-axis, axis is reversed for a clearer depiction). Dashed line indicates the cut off between the +TReg
responder (below the dashed line) and the +TReg non-responder (above the dashed line). (B) Adoptive CD4+ TReg transfer did not reshape the unfavorable CD8+
TEFF/CD4+ TReg ratio. (C) Engraftment of CD4+CD25++ T cells 1 d post-surgery is elevated in both, the +TReg responder (n = 4) and +TReg non-responder (n =
3) in comparison to the control group (n = 6). 45BV, total bone volume; TV, total callus volume; BV/TV, ratio of BV to TV; Mann–Whitney U-test.
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Enhanced Accumulation of CD8+ T Cells in
the Fracture Hematoma of Patients With
Impaired Fracture Healing
To further confirm the effect of the systemically found elevated
TEMRA cell count the fracture hematoma of these patient was
evaluated for these cells. To address this issue, we applied a
recently developed, easily applicable advanced technology to
analyze immune cell subset composition from tissue samples
based on CD3+-, TReg- and CD8+-specific epigenetic pattern
at tissue-derived DNA (30–32). Fracture hematoma composition
does not simply reflect the repertoire of blood leukocytes but
is enriched by TEFF cells attracted actively to the fracture
environment. The almost two times higher levels of CD8+ T cells
in the hematoma of impaired vs. normal healing patients support
the hypothesis that CD8+ TEFF accumulate in the fracture
hematoma, although statistical significance was not yet reached
as only a low number of fracture hematoma samples was available
for the analysis (Figure 4B).
In a next step, we analyzed the observed tight
interconnectivity between the CD8+ TEFF and CD4+ TReg
ratio and the bone healing outcome in our human patient
cohort. Interestingly, we observed an elevated percentage of
CD4+ TReg in the peripheral blood of impaired healing patients.
This could be interpreted as an intrinsic effort to counteract the
higher CD8+ TEFF level that was however, not able to reverse
the negative impact of the high CD8+ TEMRA/CD4+ TReg
ratio in those patients (Figure 5A; p < 0.001). This result is in
accordance with the data of the mouse experiment. Remarkably,
this imbalance of CD8+ TEFF/CD4+ TReg was also reflected in
the facture hematoma (Figure 5B). Impaired fracture healing
FIGURE 4 | Impaired bone healing correlates with an elevated CD8+ TEMRA level in both the peripheral blood as well as in the local fracture hematoma of patients.
(A) Results of the flow cytometry analyses of terminally differentiated CD8+ effector T cells (CD8+TEMRA ) in the peripheral blood of fracture patients at the time of
operation are shown. Impaired fracture healing patients showed a significantly higher frequency of CD45+CD3+CD8+CD57+CD28- T cells (CD57+CD28-+ in % of
CD45+CD3+CD8+ T cells) compared to the normal healing patients indicates a dramatic increase of CD8+ TEMRA: n = 12 for the impaired healing group, n = 23 for
the normal healing group. (B) Quantification of CD8+ T cells in the hematoma region of fracture healing patients by epigenetic qPCR analysis. Impaired fracture
healing patients showed an elevated level of CD8+ T cells in the local fracture area: n =5 for the impaired healing group, n = 3 for the normal healing group (C,D)
Representative x-ray images from the study cohort over a period of 15 months including the pre-surgery as well as the 6 and 15 months post-surgery states of
fracture healing of an impaired healing (C) and a normal healing (D) patient, respectively. Student’s t-test.
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patients showed a significantly higher CD8+ T cells/CD4+ TReg
ratio without overlap between the two groups, ranging from 3.0
to 6.0 and 1.2 to 2.7 in patients who showed an impaired and
normal healing outcome, respectively (p= 0.043).
These findings demonstrate that the ratios of CD8+ TEFF
to CD4+ TReg in the peripheral blood are mirrored by
those within the fracture hematoma. This cellular correlation
between the periphery and the site of injury further highlights
the significance of the balance of pro-inflammatory CD8+
TEFF to anti-inflammatory CD4+ TReg for a successful bone
healing process.
DISCUSSION
Our study demonstrates the relevance of the T cell subset
composition for regeneration using bone healing in a murine
osteotomy model as well as in patients. Enhanced CD8+
TEFF/CD4+ TReg ratios both in peripheral blood and locally in
the fracture hematoma were associated with an impaired bone
healing outcome.
The data indicates that the TEFF/TReg ratio could be a
predictive biomarker for bone healing. However, as flow
cytometry analysis from hematoma is hardly applicable for the
clinical routine, we applied a recently developed fast epigenetic
method allowing T cell subset quantification in tissue specimen
(30–32) that could be further developed into an intraoperative
diagnostic tool. This would enable a stratification of patients in
potential need of additional treatments at the time of the initial
fracture treatment.
This study clearly demonstrated that the model used for
an experimental evaluation of a hypothesis should be carefully
considered. While the results in the SPF housed mice indicated
that a treatment enhancing TReg percentages shows 100% healing
enhancement changing the model to one with a higher immune
experience (and thus a model that is closer to the patient
situation) changed this result to only 50% healing success.
What is even more alarming is that the other 50% instead of
showing an unchanged healing outcome revealed a significantly
impaired healing. This indicates that in cases of an unbalanced
immune response otherwise supportive immune cells can turn
into detrimental cells for the healing process.
FIGURE 5 | Impaired fracture healing correlates with an elevated level of CD4+ TReg and a higher ratio of CD8+ TEMRA/CD4+ TReg. (A) Results of the flow
cytometry analyses of the CD4+ TReg and the ratio CD8+TEMRA/CD4+TReg in the peripheral blood of fracture patients at the time of operation are shown. Impaired
fracture healing patients showed slightly elevated levels of CD45+CD3+CD4+CD25highCD127low TReg (CD25highCD127low in % of CD45+CD3+CD4+)
compared to the normal healing patients indicates a partial, but not sufficient compensatory effect. The ratio of CD8+TEMRA/CD4+TReg was significantly higher in
patients with a delayed healing: n = 12 for the impaired healing group, n = 23 for the normal healing group. (B) Impaired fracture healing patients showed a
significantly higher ratio of CD8+T cells/CD4+ TReg in the hematoma region demonstrating an insufficient compensatory effect of the CD4+ TReg in the impaired
fracture healing patients: n =5 for the impaired healing group, n = 3 for the normal healing group. Student’s t-test.
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As in human beings, non-SPF housed mice, even if kept in
the same cage, show an intragroup heterogeneity regarding the
TEFF/TReg balance in the blood and secondary immune organs. In
mice with very high TEFF/TReg ratio the adoptive transfer of TReg
could not rescue this imbalance measured immediately after cell
transfer in blood samples as well as at the end of 21 d follow-up
in immune organs even though engraftment was confirmed. This
unsuccessful rebalancing of the TEFF/TReg ratio was associated
not only with a lack of benefit of the TReg transfer but worsened
the healing even more. For our immune-experienced mice, we
applied a relative short exposure time of 4 weeks in the non-
SPF housing. Therefore, the observed findings and differences in
the non-SPF mice in comparison to the SPF mice are even more
astonishing. In comparison, the changes in the adaptive immune
system visible after 4 weeks of exposure were not as pronounced
as seen in an aged human being. Therefore, the ratios in the
mouse model cannot be transferred toward patients.
How can TEFF cells affect bone healing? In fact, we could
recently show (17) that CD8+ TEFF produce high amounts
of inflammatory cytokines, such as IFNγ and TNFα even
without costimulatory signals. Their strong inflamed tissue
homing properties allow them to deliver those cytokines at
fracture sites. Although some local inflammation is beneficial
for triggering endogenous regeneration post-fracture (38), too
much of “a beautiful thing” can have worsening effects, as shown
by inhibition of differentiation of osteogenic precursors in the
presence of supernatants of CD8+ TEFF, an effect that could be
converted by neutralizing TNFα and IFNγ (17).
How might TReg control the TEFF response in at least half of
the immune-experienced mice with pre-established TEFF cells?
The positive effects of TReg might be explained by the prevention
of an imbalanced TEFF/TReg ratio as a result of TReg blocking
memory/effector T cells at multiple checkpoints (34): TReg can
inhibit the cytokine release and proliferation of TEFF cells by cell-
cell contact dependent and independent mechanisms. This seems
to be related at least partly to adenosine formation and metabolic
competition (e.g., tryptophan pathway) as shown before (34).
In summary, our findings confirm our recent data that
suggested a negative impact of CD8+ TEMRA on bone fracture
healing in patients (17) but extend these observations further
by demonstrating the relevance of the systemic and local
balance between effector and regulatory mechanisms (TEFF/TReg
ratio). Moreover, our data indicate that a CD4+ TReg based
immunomodulation is feasible to further bone regeneration but
its efficiency is dependent on the recipient’s immune status,
especially of a balanced adaptive immunity (Figure 6).
The strong link between the pre-surgery immune cell ratio
and the healing outcome was clearly demonstrated in our
animal model.
Considering the fact that the non-responder mice show the
tendency of even worse healing compared to the responder and
even compared to the control mice the following considerations
could be made. It is already well-known that CD4+ TReg
are not a committed stable T cell subpopulation. Dependent
on the inflammatory environment, several studies reported a
loss of FOXP3 expression by CD4+ TReg accompanied by
the loss of their suppressive activity (39, 40). Furthermore,
CD4+ TReg cannot only lose their suppressive capacity but can
also convert to CD4+ TEFF cells such as Th17 cells (40–42).
For Th17 cells controversial effects on bone cells have been
reported. They can stimulate the formation of osteoclasts by the
production of Receptor Activator of NF-κB Ligand (RANKL),
either directly by themselves or indirectly via osteoblasts or
synovial fibroblasts. Furthermore, it is described that Th17
FIGURE 6 | Interdependency of the immune status and the healing outcome after bone fracture. The ratio of CD8+ effector T cells (CD8+ TEFF) to CD4+ regulatory T
cells (CD4+ TReg) affects the healing outcome after bone fracture. Under normal healing conditions, the T cell ratio is balanced. An elevated amount of CD8+ TEFF
relative to CD4+ TReg is unfavorable for successful healing. A shifted balance in the CD4+ TReg direction improves bone fracture healing.
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cells act pro-osteogenic. Additionally, in the context of several
bone related disorders, the underlying cause is postulated
to be an imbalance of the ratio between Th17 cells and
CD4+ TReg (43, 44).
In vitro studies using murine or human CD4+ TReg have
demonstrated a possible transition between CD4+ TReg and IL-
17 producing (Th17) T cells. For example, Xu et al. reported
that this transition is IL-6 dependent (41). Using co-culture
setups, another study showed that murine CD4+ TReg can
obtain the expression of Rorγt, the master transcription factor
of Th17 cells (45). Studies with human CD4+ TReg also
revealed this conversion between CD4+ TReg and Th17 cells
(46, 47). One possible explanation for the observed non-
responsiveness of some CD4+ TReg enriched animals could,
therefore, be a potential transition of the pro-regenerative
CD4+ TReg into an anti-regenerative Th17-like phenotype. This
hypothesis could be more directly verified by findings from
Zhou and colleagues (40). They evaluated the stability and fate
of (initially) Foxp3+ CD4+ TReg under homeostatic as well
as pathogenic conditions in vivo by using a combined Foxp3-
GFP-Cre/ R26-YFP mice system. This mouse model enables
the detection of the induction or downregulation of Foxp3
expression and further allows to track the cell fate of Foxp3+
CD4+ TReg. Zhou and colleagues showed that the strength of
loss of Foxp3 expression from CD4+ TReg was dependent on
the microenvironment and was stronger in inflamed tissues
in autoimmune conditions. Furthermore, they showed that
these converted Foxp3- “CD4+ TReg” express memory cell
marker and pro-inflammatory cytokines like IFNγ and IL-
17. Thus, there is evidence that a strong pro-inflammatory
microenvironment bears the risk to promote the transition of
Foxp3+ to Foxp3- CD4+T cells. If such a transition is happening
during bone fracture healing in elevated pro-inflammatory
conditions, this could explain the observed impaired healing
in our mice where CD4+ TReg transfer did not overcome the
pro-inflammatory microenvironment resulting from the high
TEFF levels.
CONCLUSION
Bone fracture healing is a highly complex process. The presented
and discussed human and mice data demonstrate the strong
interdependency between the adaptive immunity and the bone
system in the context of bone healing. They further highlight how
well-regulated the interplay of different (immune) cell subtypes
has to be to promote regeneration. Due to the observed findings
at both sides, locally at the fracture as well as systemically in
the peripheral blood, this cellular interplay is probably not only
crucial for bone fracture repair but also for the healing capacity
of other injured tissues. With regard to clinical translation,
our data indicate the advantage of a TEFF/TReg ratio analysis,
allowing to identify patients at risk in an early stratification and
thereby predict already preoperatively the healing potential after
bony injury. A prospective multicenter study (>600 patients)
is currently ongoing to confirm the promising potential of
the CD8+ TEMRA/CD4+ TReg ratio as a potential biomarker
for predicting the healing outcome in human bone fracture
patients. Therefore, the cellular interplay could be used to
better understand regulatory mechanisms guiding regenerative
processes and thus could reveal possible novel target points
for (immunomodulatory) treatment strategies to therapeutically
support and improve impaired tissue repair.
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